

In order to face the development of its activities, ASIT biotech is currently seeking a

Junior Project Leader Development Operations

The Junior Project Leader Development Operations will join the Product, Process and Analytical Development team responsible for the development of all ASIT biotech products from conception to completion. He will interact daily with cross-functional teams from Pre-Clinical, Manufacturing Operations and Quality Control.

Main responsibilities will include

- Plan, execute and report experiments in accordance with the overall development objectives,
- Conduct in depth analysis of results and draw conclusions,
- Present and communicate results/findings in internal meetings,
- Interface with manufacturing and quality control to ensure successful technology transfer,
- Produce and maintain proper project documentation in accordance with internal and external requirements.

Requirements and competencies

- Master in molecular biology, chemistry, biochemistry or equivalent discipline,
- Previous experience in protein production, purification and characterization will be an asset,
- Strong analytical skills specific to operational activities,
- Utilize strong problem-solving skills to recognize problems and develop corrective actions plan,
- Strong cross-functional written and verbal communication skills,
- Ability to work in a team,
- Cross-functional collaboration skills with the ability to network with different functional groups/partners,
- Ability to work independently with a minimum of direction,
- Results orientation with a proven ability to get things done,
- Organizational effectiveness with an ability to structure projects, work flows and processes,
- Willingness to work in fast paced and dynamic team environment,
- Agility,
- Positive attitude, plenty of energy, and excellent interpersonal skills,
- Driver's license holder,
- Languages: fluent in French & English.

We offer

- To join a company with a very high growth potential,
- To integrate a very competent and motivated team,
- To collaborate to the development of innovative products in a very dynamic environment,
- Attractive salary and benefit package.

Applicants should apply online with the following link:

https://www.genius-people.com/jobs/en_US/junior-project-leader-development-operations/Mk5Hb1M2dnpYRzY3UStGVEhbbWVuQT09/

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

gp-ASIT+™, our product candidate for the treatment of grass pollen rhinitis consists of a mixture of natural allergen fragments obtained from a purified specific proteinic extract from *Lolium perenne* pollen. In contrast to the synthesized peptides, the natural peptides (70% of the fragments ranging from 1,000<MW<10,000) include a wide range of epitopes that stimulate the immune system with optimal complexity.

The administration schedule of the treatment is of short duration compared with currently commercialised treatments. This constitutes a major competitive advantage to improve the acceptance and the compliance of the patients. In addition, the administration schedule includes successive injections with half of the visit dose in both arms, an innovative solution that enables the delivery of the total dose necessary for the therapeutic effect in a faster and safer way. Finally, the product candidate is formulated without adjuvant, which increases the long-term safety of the product by decreasing the local and general reactogenicity as well as the frequency of the adverse events, which represents a further advantage in markets less permissive to adjuvanted formulations (e.g. US).

Except for the clinical efficacy during natural grass pollen exposure that is investigated in the current first phase III clinical study with gp-ASIT+™, all the above-mentioned characteristics have been demonstrated in the already conducted clinical studies.

As a result, the Company believes that gp-ASIT+™ is the only short course treatment AIT product free of adjuvant that is currently in phase III clinical studies with positive and statistically significant efficacy and immunogenicity results obtained during the phase IIa and phase IIb clinical studies.

ASIT biotech has a headcount of 25 staff members, located at its headquarters in Brussels and laboratory in Liège, Belgium.

Further information can be found at: www.asitbiotech.com.